Identification

Name
Treprostinil
Accession Number
DB00374  (APRD01272)
Type
Small Molecule
Groups
Approved, Investigational
Description

Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension.

Structure
Thumb
Synonyms
  • (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
  • [[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
  • Treprostinil
  • Treprostinilo
  • Treprostinilum
  • Uniprost
External IDs
15AU81 / BW 15AU / LRX 15 / LRX-15 / U 62840 / UT 15 / UT-15
Product Ingredients
IngredientUNIICASInChI Key
Treprostinil diolamineH1FKG90039830354-48-8RHWRWEUCEXUUAV-ZSESPEEFSA-N
Treprostinil sodium7JZ75N2NT6289480-64-4IQKAWAUTOKVMLE-ZSESPEEFSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OrenitramTablet, extended release5 mg/1OralUnited Therapeutics2013-12-20Not applicableUs
OrenitramTablet, extended release.125 mg/1OralUnited Therapeutics2013-12-20Not applicableUs
OrenitramTablet, extended release2.5 mg/1OralUnited Therapeutics2013-12-20Not applicableUs
OrenitramTablet, extended release.25 mg/1OralUnited Therapeutics2013-12-20Not applicableUs
OrenitramTablet, extended release2.5 mg/1OralAvera Mc Kennan Hospital2016-07-20Not applicableUs
OrenitramTablet, extended release1 mg/1OralUnited Therapeutics2013-12-20Not applicableUs
RemodulinInjection, solution20 mg/20mLIntravenous; SubcutaneousUnited Therapeutics2002-05-22Not applicableUs
RemodulinInjection, solution200 mg/20mLIntravenous; SubcutaneousUnited Therapeutics2002-05-22Not applicableUs
RemodulinSolution5 mgIntravenous; SubcutaneousUnited Therapeutics2004-04-30Not applicableCanada
RemodulinInjection, solution50 mg/20mLIntravenous; SubcutaneousUnited Therapeutics2002-05-22Not applicableUs
Categories
UNII
RUM6K67ESG
CAS number
81846-19-7
Weight
Average: 390.5131
Monoisotopic: 390.240624198
Chemical Formula
C23H34O5
InChI Key
PAJMKGZZBBTTOY-ZFORQUDYSA-N
InChI
InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
IUPAC Name
2-{[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H,2H,3H,3aH,4H,9H,9aH-cyclopenta[b]naphthalen-5-yl]oxy}acetic acid
SMILES
[H][[email protected]]12C[[email protected]@H](O)[[email protected]](CC[[email protected]@H](O)CCCCC)[[email protected]@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1

Pharmacology

Indication

For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.

Structured Indications
Pharmacodynamics

Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed.

Mechanism of action

The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.

TargetActionsOrganism
AProstacyclin receptor
agonist
Human
APeroxisome proliferator-activated receptor delta
agonist
Human
AP2Y purinoceptor 12
agonist
Human
Absorption

Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.

Volume of distribution
  • 14 L/70 kg
Protein binding

Human plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 µ/L.

Metabolism

Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described (HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the 3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. Whether treprostinil induces these enzymes has not been studied.

Route of elimination
Not Available
Half life

Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.

Clearance
Not Available
Toxicity

Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Treprostinil.Experimental
AbciximabTreprostinil may increase the antiplatelet activities of Abciximab.Approved
AbirateroneThe metabolism of Treprostinil can be decreased when combined with Abiraterone.Approved
AcebutololTreprostinil may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Acemetacin.Approved
AcenocoumarolTreprostinil may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Treprostinil.Approved, Investigational
AliskirenTreprostinil may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aloxiprin.Experimental
AlprenololTreprostinil may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AlprostadilTreprostinil may increase the antiplatelet activities of Alprostadil.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Alteplase is combined with Treprostinil.Approved
ALX-0081The risk or severity of adverse effects can be increased when ALX-0081 is combined with Treprostinil.Investigational
AmbrisentanTreprostinil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTreprostinil may increase the hypotensive activities of Amifostine.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aminosalicylic Acid.Approved
AmiodaroneTreprostinil may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmlodipineTreprostinil may increase the hypotensive activities of Amlodipine.Approved
AnagrelideTreprostinil may increase the QTc-prolonging activities of Anagrelide.Approved
AncrodTreprostinil may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Anisodamine.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Anistreplase is combined with Treprostinil.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Antipyrine.Approved
Antithrombin III humanTreprostinil may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTreprostinil may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Treprostinil is combined with Apocynin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Treprostinil can be increased when combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Treprostinil can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinTreprostinil may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTreprostinil may increase the antiplatelet activities of Argatroban.Approved, Investigational
Arsenic trioxideTreprostinil may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTreprostinil may increase the QTc-prolonging activities of Artemether.Approved
AsenapineTreprostinil may increase the QTc-prolonging activities of Asenapine.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Astaxanthin is combined with Treprostinil.Investigational
AtenololAtenolol may increase the hypotensive activities of Treprostinil.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azelastine.Approved
AzithromycinTreprostinil may increase the QTc-prolonging activities of Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Batroxobin is combined with Treprostinil.Experimental
BecaplerminTreprostinil may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BedaquilineTreprostinil may increase the QTc-prolonging activities of Bedaquiline.Approved
BemiparinThe risk or severity of adverse effects can be increased when Bemiparin is combined with Treprostinil.Approved, Investigational
BenazeprilTreprostinil may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bendazac.Experimental
BendroflumethiazideTreprostinil may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Treprostinil.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Benoxaprofen.Withdrawn
BepridilTreprostinil may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostTreprostinil may increase the antiplatelet activities of Beraprost.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Treprostinil.Approved
BethanidineBethanidine may increase the hypotensive activities of Treprostinil.Approved
BevoniumThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Treprostinil.Experimental
BimatoprostTreprostinil may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololTreprostinil may increase the hypotensive activities of Bisoprolol.Approved
BivalirudinTreprostinil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Treprostinil.Approved, Investigational
BQ-123Treprostinil may increase the hypotensive activities of BQ-123.Investigational
BretyliumTreprostinil may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Treprostinil.Approved
BrinaseThe risk or severity of adverse effects can be increased when Brinase is combined with Treprostinil.Experimental
BrofaromineBrofaromine may increase the hypotensive activities of Treprostinil.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bufexamac.Experimental
BuflomedilTreprostinil may increase the antiplatelet activities of Buflomedil.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bumadizone.Experimental
BupranololTreprostinil may increase the hypotensive activities of Bupranolol.Approved
ButylphthalideTreprostinil may increase the antiplatelet activities of Butylphthalide.Investigational
CadralazineCadralazine may increase the hypotensive activities of Treprostinil.Experimental
CafedrineTreprostinil may increase the hypotensive activities of Cafedrine.Investigational
Candesartan cilexetilTreprostinil may increase the hypotensive activities of Candesartan.Approved
CandoxatrilTreprostinil may increase the hypotensive activities of Candoxatril.Experimental
CangrelorTreprostinil may increase the antiplatelet activities of Cangrelor.Approved
CapecitabineThe metabolism of Treprostinil can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilTreprostinil may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Treprostinil can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Treprostinil is combined with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Treprostinil.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTreprostinil may increase the hypotensive activities of Carteolol.Approved
CarvedilolTreprostinil may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Celecoxib.Approved, Investigational
CeliprololTreprostinil may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Treprostinil can be increased when it is combined with Ceritinib.Approved
CertoparinTreprostinil may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideTreprostinil may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineTreprostinil may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Treprostinil.Approved
CholecalciferolThe metabolism of Treprostinil can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Choline magnesium trisalicylate.Approved
CicletanineTreprostinil may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilTreprostinil may increase the hypotensive activities of Cilazapril.Approved
CilostazolTreprostinil may increase the antiplatelet activities of Cilostazol.Approved
CiprofloxacinTreprostinil may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideTreprostinil may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramTreprostinil may increase the QTc-prolonging activities of Citalopram.Approved
Citric AcidTreprostinil may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinTreprostinil may increase the QTc-prolonging activities of Clarithromycin.Approved
ClonidineClonidine may increase the hypotensive activities of Treprostinil.Approved
ClonixinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Clonixin.Approved
ClopidogrelTreprostinil may increase the antiplatelet activities of Clopidogrel.Approved, Nutraceutical
CloranololTreprostinil may increase the hypotensive activities of Cloranolol.Experimental
CloricromenTreprostinil may increase the antiplatelet activities of Cloricromen.Experimental
ClorindioneThe risk or severity of adverse effects can be increased when Clorindione is combined with Treprostinil.Experimental
ClotrimazoleThe metabolism of Treprostinil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineTreprostinil may increase the QTc-prolonging activities of Clozapine.Approved
CrisaboroleThe metabolism of Treprostinil can be decreased when combined with Crisaborole.Approved
CrizotinibTreprostinil may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineTreprostinil may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Treprostinil is combined with Curcumin.Investigational
CyclopenthiazideTreprostinil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Treprostinil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideTreprostinil may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Treprostinil is combined with D-Limonene.Investigational
Dabigatran etexilateTreprostinil may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Treprostinil can be decreased when it is combined with Dabrafenib.Approved
DalteparinTreprostinil may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTreprostinil may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTreprostinil may increase the anticoagulant activities of Darexaban.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Treprostinil.Approved, Investigational
DefibrotideTreprostinil may increase the antiplatelet activities of Defibrotide.Approved, Investigational
DelaprilTreprostinil may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Treprostinil can be decreased when combined with Delavirdine.Approved
dersalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with dersalazine.Investigational
DeserpidineTreprostinil may increase the hypotensive activities of Deserpidine.Approved
DesirudinTreprostinil may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Desmoteplase is combined with Treprostinil.Investigational
DextranTreprostinil may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Treprostinil may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Treprostinil may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Treprostinil may increase the anticoagulant activities of Dextran 75.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Treprostinil.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diclofenac.Approved, Vet Approved
DicoumarolTreprostinil may increase the anticoagulant activities of Dicoumarol.Approved
diethylnorspermineTreprostinil may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Treprostinil.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Treprostinil.Approved
DiphenadioneThe risk or severity of adverse effects can be increased when Diphenadione is combined with Treprostinil.Experimental
DipyridamoleTreprostinil may increase the antiplatelet activities of Dipyridamole.Approved
DisopyramideTreprostinil may increase the QTc-prolonging activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Ditazole is combined with Treprostinil.Approved, Withdrawn
DofetilideTreprostinil may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronTreprostinil may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneTreprostinil may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DorzolamideTreprostinil may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Treprostinil can be decreased when combined with Dosulepin.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Treprostinil.Approved
DronedaroneTreprostinil may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolTreprostinil may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Treprostinil is combined with E-6201.Investigational
Edetic AcidTreprostinil may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTreprostinil may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Treprostinil can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineTreprostinil may increase the hypotensive activities of Efonidipine.Approved
EliglustatTreprostinil may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilTreprostinil may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTreprostinil may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Treprostinil.Experimental
EnoxaparinTreprostinil may increase the anticoagulant activities of Enoxaparin.Approved
EpanololTreprostinil may increase the hypotensive activities of Epanolol.Experimental
EpinastineTreprostinil may increase the antiplatelet activities of Epinastine.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Treprostinil is combined with Epirizole.Approved
EplivanserinTreprostinil may increase the antiplatelet activities of Eplivanserin.Investigational
eplivanserineTreprostinil may increase the antiplatelet activities of eplivanserine.Investigational
EpoprostenolTreprostinil may increase the antiplatelet activities of Epoprostenol.Approved
EprosartanTreprostinil may increase the hypotensive activities of Eprosartan.Approved
EptifibatideTreprostinil may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
ErythromycinTreprostinil may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramTreprostinil may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etanercept.Approved, Investigational
EthanolEthanol can cause an increase in the absorption of Treprostinil resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
EthenzamideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTreprostinil may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Treprostinil can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Treprostinil is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Felbinac.Experimental
FelodipineTreprostinil may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenbufen.Approved
FenoldopamTreprostinil may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Feprazone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Fibrinolysin is combined with Treprostinil.Investigational
FlecainideTreprostinil may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Treprostinil can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Treprostinil can be decreased when combined with Fluconazole.Approved
FluindioneTreprostinil may increase the anticoagulant activities of Fluindione.Investigational
FlunixinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Treprostinil can be decreased when combined with Fluorouracil.Approved
FluoxetineTreprostinil may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolTreprostinil may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurbiprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Flurbiprofen.Approved, Investigational
FluvastatinThe metabolism of Treprostinil can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Treprostinil can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxTreprostinil may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTreprostinil may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosinoprilTreprostinil may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Treprostinil can be decreased when it is combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Treprostinil.Approved, Investigational, Vet Approved
GabexateTreprostinil may increase the anticoagulant activities of Gabexate.Investigational
Gadobenic acidTreprostinil may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinTreprostinil may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinTreprostinil may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTreprostinil may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Treprostinil is combined with Guacetisal.Experimental
GuanabenzTreprostinil may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Treprostinil.Approved
GuanazodineTreprostinil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Treprostinil.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Treprostinil.Approved, Investigational
GuanoclorTreprostinil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTreprostinil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTreprostinil may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolTreprostinil may increase the QTc-prolonging activities of Haloperidol.Approved
HarmalineHarmaline may increase the hypotensive activities of Treprostinil.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Hemoglobin crosfumaril.Experimental
HeparinTreprostinil may increase the anticoagulant activities of Heparin.Approved, Investigational
HexamethoniumTreprostinil may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Treprostinil.Experimental
HydralazineHydralazine may increase the hypotensive activities of Treprostinil.Approved
HydrochlorothiazideTreprostinil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTreprostinil may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxytyrosolTreprostinil may increase the antiplatelet activities of Hydroxytyrosol.Investigational
IbudilastTreprostinil may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ibuproxam.Withdrawn
IbutilideTreprostinil may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe risk or severity of adverse effects can be increased when Treprostinil is combined with Icatibant.Approved
Icosapent ethylTreprostinil may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdraparinuxTreprostinil may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilTreprostinil may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanTreprostinil may increase the antiplatelet activities of Ifetroban.Investigational
IloperidoneTreprostinil may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostTreprostinil may increase the antiplatelet activities of Iloprost.Approved, Investigational
ImidaprilTreprostinil may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Imidazole salicylate.Experimental
IndapamideTreprostinil may increase the hypotensive activities of Indapamide.Approved
IndenololTreprostinil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Treprostinil can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Treprostinil.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Treprostinil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Treprostinil.Withdrawn
IrbesartanThe metabolism of Treprostinil can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Treprostinil.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Treprostinil.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Kebuzone.Experimental
KetanserinTreprostinil may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Treprostinil can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketorolac.Approved
LabetalolTreprostinil may increase the hypotensive activities of Labetalol.Approved
LacidipineTreprostinil may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostTreprostinil may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Leflunomide.Approved, Investigational
LenvatinibTreprostinil may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinTreprostinil may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineTreprostinil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LetaxabanTreprostinil may increase the anticoagulant activities of Letaxaban.Investigational
LeuprolideTreprostinil may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinTreprostinil may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Treprostinil.Approved, Investigational
LinsidomineTreprostinil may increase the antiplatelet activities of Linsidomine.Experimental
LisinoprilTreprostinil may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lisofylline.Investigational
LobeglitazoneThe metabolism of Treprostinil can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineTreprostinil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Treprostinil can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Treprostinil can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Loxoprofen.Approved, Investigational
LumacaftorThe serum concentration of Treprostinil can be decreased when it is combined with Lumacaftor.Approved
LumefantrineTreprostinil may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lumiracoxib.Approved, Investigational
MacitentanTreprostinil may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Magnesium salicylate.Approved
ManidipineTreprostinil may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Treprostinil.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Treprostinil.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mefenamic acid.Approved
MelagatranTreprostinil may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Treprostinil is combined with Metamizole.Investigational, Withdrawn
MethadoneTreprostinil may increase the QTc-prolonging activities of Methadone.Approved
MethoserpidineTreprostinil may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaTreprostinil may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Treprostinil.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Treprostinil.Approved, Investigational
MetipranololTreprostinil may increase the hypotensive activities of Metipranolol.Approved
MetolazoneTreprostinil may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the hypotensive activities of Treprostinil.Approved, Investigational
MetyrosineTreprostinil may increase the hypotensive activities of Metyrosine.Approved
MibefradilTreprostinil may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidostaurinThe metabolism of Treprostinil can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Treprostinil can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneTreprostinil may increase the antiplatelet activities of Milrinone.Approved
MinaprineMinaprine may increase the hypotensive activities of Treprostinil.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Treprostinil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Treprostinil.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Treprostinil.Approved
MoexiprilTreprostinil may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Treprostinil.Approved, Investigational
MoxifloxacinTreprostinil may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Treprostinil.Approved, Investigational
MuzolimineTreprostinil may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nabumetone.Approved
NadololTreprostinil may increase the hypotensive activities of Nadolol.Approved
NadroparinTreprostinil may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Naftifine.Approved
NaftopidilTreprostinil may increase the antiplatelet activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Naproxen.Approved, Vet Approved
NebivololTreprostinil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Treprostinil.Withdrawn
NicardipineThe metabolism of Treprostinil can be decreased when combined with Nicardipine.Approved
NicorandilTreprostinil may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Niflumic Acid.Approved
NiguldipineTreprostinil may increase the hypotensive activities of Niguldipine.Experimental
NilotinibTreprostinil may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineTreprostinil may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineTreprostinil may increase the hypotensive activities of Nimodipine.Approved
NisoldipineTreprostinil may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineTreprostinil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Treprostinil.Approved
ObinutuzumabTreprostinil may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Treprostinil.Withdrawn
OfloxacinTreprostinil may increase the QTc-prolonging activities of Ofloxacin.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Treprostinil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olsalazine.Approved
OmapatrilatTreprostinil may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Treprostinil can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronTreprostinil may increase the QTc-prolonging activities of Ondansetron.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Orgotein.Vet Approved
OtamixabanTreprostinil may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxaprozin.Approved
OxprenololTreprostinil may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxyphenbutazone.Approved, Withdrawn
OzagrelThe risk or severity of adverse effects can be increased when Ozagrel is combined with Treprostinil.Investigational
PaliperidoneTreprostinil may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatTreprostinil may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Treprostinil.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Parnaparin is combined with Treprostinil.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Parthenolide.Investigational
PazopanibTreprostinil may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololTreprostinil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineTreprostinil may increase the QTc-prolonging activities of Pentamidine.Approved
PentoliniumTreprostinil may increase the hypotensive activities of Pentolinium.Approved
Pentosan PolysulfateTreprostinil may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Treprostinil.Approved, Investigational
PerflutrenTreprostinil may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilTreprostinil may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Treprostinil.Approved
PhenindioneTreprostinil may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the hypotensive activities of Treprostinil.Withdrawn
PhenobarbitalThe serum concentration of Treprostinil can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineTreprostinil may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Treprostinil.Withdrawn
PhenprocoumonTreprostinil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolamineTreprostinil may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Treprostinil can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PicotamideTreprostinil may increase the antiplatelet activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pimecrolimus.Approved, Investigational
PimozideTreprostinil may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilPinacidil may increase the hypotensive activities of Treprostinil.Withdrawn
PindololTreprostinil may increase the hypotensive activities of Pindolol.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Treprostinil.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Treprostinil.Withdrawn
PolythiazideTreprostinil may increase the hypotensive activities of Polythiazide.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pranoprofen.Experimental, Investigational
PrasugrelTreprostinil may increase the antiplatelet activities of Prasugrel.Approved
PrazosinPrazosin may increase the hypotensive activities of Treprostinil.Approved
PrimaquineTreprostinil may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Treprostinil can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideTreprostinil may increase the QTc-prolonging activities of Procainamide.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Proglumetacin.Experimental
PromazineTreprostinil may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Propacetamol.Approved, Investigational
PropafenoneTreprostinil may increase the QTc-prolonging activities of Propafenone.Approved
PropranololTreprostinil may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Proquazone.Experimental
Protein CTreprostinil may increase the anticoagulant activities of Protein C.Approved
Protein S humanTreprostinil may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTreprostinil may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299The risk or severity of adverse effects can be increased when Treprostinil is combined with PTC299.Investigational
PyrimethamineThe metabolism of Treprostinil can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineTreprostinil may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilTreprostinil may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineTreprostinil may increase the QTc-prolonging activities of Quinidine.Approved
QuinineTreprostinil may increase the QTc-prolonging activities of Quinine.Approved
RamatrobanTreprostinil may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilRamipril may increase the hypotensive activities of Treprostinil.Approved
RasagilineRasagiline may increase the hypotensive activities of Treprostinil.Approved
RemikirenRemikiren may increase the hypotensive activities of Treprostinil.Approved
RescinnamineTreprostinil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Treprostinil.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.Approved
ReviparinTreprostinil may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelTreprostinil may increase the antiplatelet activities of Ridogrel.Approved
RifampicinThe serum concentration of Treprostinil can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Treprostinil can be decreased when it is combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Treprostinil.Investigational
RiociguatTreprostinil may increase the hypotensive activities of Riociguat.Approved
RituximabTreprostinil may increase the hypotensive activities of Rituximab.Approved
RivaroxabanTreprostinil may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Rosiglitazone is combined with Treprostinil.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Treprostinil.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salsalate.Approved
SaprisartanTreprostinil may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirTreprostinil may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SarpogrelateTreprostinil may increase the antiplatelet activities of Sarpogrelate.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Saruplase is combined with Treprostinil.Experimental
SecobarbitalThe serum concentration of Treprostinil can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Treprostinil.Approved, Investigational, Vet Approved
SelexipagTreprostinil may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Treprostinil is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Treprostinil is combined with Serrapeptase.Investigational
SevofluraneTreprostinil may increase the antiplatelet activities of Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
SitaxentanTreprostinil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Treprostinil can be decreased when combined with Sorafenib.Approved, Investigational
SotalolTreprostinil may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilTreprostinil may increase the hypotensive activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when Treprostinil is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.Approved, Investigational
SulfadiazineThe metabolism of Treprostinil can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Treprostinil can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Treprostinil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulindac.Approved
SulodexideTreprostinil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Treprostinil is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
TalinololTreprostinil may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tarenflurbil.Investigational
TelavancinTreprostinil may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTreprostinil may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanTreprostinil may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilTreprostinil may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Tenecteplase is combined with Treprostinil.Approved
TenidapThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Teriflunomide.Approved
TerlipressinTreprostinil may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneTreprostinil may increase the antiplatelet activities of Tesmilifene.Investigational
TetrabenazineTreprostinil may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetrahydropalmatineTreprostinil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineTreprostinil may increase the hypotensive activities of Theodrenaline.Investigational
ThioridazineTreprostinil may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tiaprofenic acid.Approved
TiboloneTreprostinil may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Treprostinil can be decreased when combined with Ticagrelor.Approved
TiclopidineTreprostinil may increase the antiplatelet activities of Ticlopidine.Approved
TicrynafenTreprostinil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Treprostinil.Approved
TinoridineThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Tinzaparin is combined with Treprostinil.Approved
TioclomarolThe risk or severity of adverse effects can be increased when Tioclomarol is combined with Treprostinil.Experimental
TirofibanTreprostinil may increase the antiplatelet activities of Tirofiban.Approved
TolazolineTreprostinil may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Treprostinil can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolmetin.Approved
TolonidineTreprostinil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Treprostinil.Approved
TopiroxostatThe metabolism of Treprostinil can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Treprostinil.Approved
ToremifeneTreprostinil may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrandolaprilTreprostinil may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Treprostinil.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Treprostinil.Approved
TrapidilTreprostinil may increase the antiplatelet activities of Trapidil.Approved
TravoprostTravoprost may increase the hypotensive activities of Treprostinil.Approved
TribenosideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tribenoside.Experimental
TrichlormethiazideTreprostinil may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TriflusalTreprostinil may increase the antiplatelet activities of Triflusal.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Treprostinil.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrimethoprimThe metabolism of Treprostinil can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Treprostinil is combined with Triptolide.Investigational
TroxerutinTreprostinil may increase the anticoagulant activities of Troxerutin.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Treprostinil.Approved, Investigational
UnoprostoneTreprostinil may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Treprostinil.Investigational
UrokinaseThe risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Treprostinil is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Treprostinil can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Treprostinil can be decreased when combined with Valsartan.Approved, Investigational
VandetanibTreprostinil may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the antihypertensive activities of Treprostinil.Approved
VemurafenibTreprostinil may increase the QTc-prolonging activities of Vemurafenib.Approved
VincamineTreprostinil may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTreprostinil may increase the hypotensive activities of Vinpocetine.Investigational
VorapaxarTreprostinil may increase the antiplatelet activities of Vorapaxar.Approved
VoriconazoleThe metabolism of Treprostinil can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinTreprostinil may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTreprostinil may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XipamideTreprostinil may increase the hypotensive activities of Xipamide.Experimental
XylometazolineTreprostinil may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Treprostinil.Approved, Vet Approved
ZafirlukastThe metabolism of Treprostinil can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneTreprostinil may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilTreprostinil may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zomepirac.Withdrawn
ZuclopenthixolTreprostinil may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh, "TREPROSTINIL PRODUCTION." U.S. Patent US20110319641, issued December 29, 2011.

US20110319641
General References
Not Available
External Links
Human Metabolome Database
HMDB14518
PubChem Compound
6918140
PubChem Substance
46504572
ChemSpider
5293353
ChEBI
50861
ChEMBL
CHEMBL1237119
Therapeutic Targets Database
DAP001214
PharmGKB
PA164768801
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Treprostinil
ATC Codes
B01AC21 — Treprostinil
AHFS Codes
  • 48:48.00 — Vasodilating Agents
FDA label
Download (223 KB)
MSDS
Download (17.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentRaynaud's Phenomenon1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
1CompletedTreatmentPulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)2
1, 2CompletedTreatmentHealthy Volunteers1
1, 2RecruitingTreatmentIschemia Reperfusion Injury1
1, 2RecruitingTreatmentScleroderma, Systemic1
2CompletedTreatmentPAH1
2Not Yet RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
2Not Yet RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
2RecruitingPreventionRespiratory Distress Syndrome, Adult1
2RecruitingSupportive CareCongenital Heart Disease (CHD)1
2RecruitingTreatmentCalcinosis / Sclerosis, Progressive Systemic1
2RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentPersistent Pulmonary Hypertension of the Newborn1
2TerminatedTreatmentIdiopathic Pulmonary Fibrosis (IPF) / Pulmonary Hypertension (PH)1
2TerminatedTreatmentSclerosis, Progressive Systemic1
2WithdrawnTreatmentPulmonary Fibrosis / Pulmonary Hypertension (PH)1
2, 3Enrolling by InvitationTreatmentCombined Pulmonary Fibrosis and Emphysema / Interstitial Lung Disease (ILD) / Pulmonary Hypertension (PH)1
2, 3RecruitingTreatmentCombined Pulmonary Fibrosis and Emphysema / Interstitial Lung Disease (ILD) / Pulmonary Hypertension (PH)1
2, 3TerminatedTreatmentPeripheral Vascular Disease (PVD)1
2, 3WithdrawnPreventionTransplantation, Liver1
3Active Not RecruitingTreatmentNon-operable Chronic Thromboembolic Pulmonary Hypertension1
3CompletedTreatmentPulmonary Hypertension (PH)2
3Not Yet RecruitingPreventionPulmonary Hypertension (PH)1
3Not Yet RecruitingTreatmentPulmonary Hypertension Associated With Sickle Cell Disease1
3RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF) / Pulmonary Hypertension (PH)1
3RecruitingTreatmentPulmonary Hypertension Associated With HFpEF1
3TerminatedTreatmentCritical Limb Ischemia (CLI) / Foot Ulcers / Peripheral Vascular Disease (PVD) / Rest Leg Pain1
3Unknown StatusTreatmentIdiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Disease (ILD) / Pulmonary Arterial Hypertension (PAH)1
3WithdrawnTreatmentPulmonary Arterial Hypertension (PAH)1
4CompletedTreatmentPulmonary Arterial Hypertension (PAH)4
4CompletedTreatmentPulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)1
4CompletedTreatmentPulmonary Hypertension (PH)1
4TerminatedTreatmentPulmonary Arterial Hypertension (PAH)2
4TerminatedTreatmentPulmonary Hypertension (PH)2
4Unknown StatusTreatmentPulmonary Hypertension (PH)1
4WithdrawnTreatmentPulmonary Arterial Hypertension (PAH)2
Not AvailableCompletedNot AvailablePortopulmonary Hypertension / Pulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)1
Not AvailableCompletedNot AvailablePulmonary Arterial Hypertension (PAH)1
Not AvailableRecruitingNot AvailablePulmonary Arterial Hypertension (PAH)1
Not AvailableRecruitingTreatmentFontan Operation / Univentricular heart1
Not AvailableTerminatedSupportive CareCongenital Heart Disease (CHD)1

Pharmacoeconomics

Manufacturers
  • United therapeutics corp
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral.125 mg/1
Tablet, extended releaseOral.25 mg/1
Tablet, extended releaseOral1 mg/1
Tablet, extended releaseOral2.5 mg/1
Tablet, extended releaseOral5 mg/1
Injection, solutionIntravenous; Subcutaneous100 mg/20mL
Injection, solutionIntravenous; Subcutaneous20 mg/20mL
Injection, solutionIntravenous; Subcutaneous200 mg/20mL
Injection, solutionIntravenous; Subcutaneous50 mg/20mL
SolutionIntravenous; Subcutaneous1 mg
SolutionIntravenous; Subcutaneous10 mg
SolutionIntravenous; Subcutaneous2.5 mg
SolutionIntravenous; Subcutaneous5 mg
InhalantOral1.74 mg/2.9mL
Prices
Unit descriptionCostUnit
Remodulin 10 mg/ml vial737.0USD ml
Remodulin 5 mg/ml vial368.5USD ml
Tyvaso inhalation starter kit185.8USD ml
Remodulin 2.5 mg/ml vial184.25USD ml
Tyvaso 1.74 mg/2.9 ml solution174.55USD ml
Tyvaso inhalation refill kit165.68USD ml
Remodulin 1 mg/ml vial73.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5153222No1994-10-062014-10-06Us
US8653137No2008-09-052028-09-05Us
US8658694No2008-09-052028-09-05Us
US7999007No2009-03-292029-03-29Us
US9199908No2004-05-242024-05-24Us
US6765117No1997-10-242017-10-24Us
US8497393No2008-12-152028-12-15Us
US6521212No1998-11-132018-11-13Us
US6756033No1998-11-132018-11-13Us
US7544713No2004-07-142024-07-14Us
US9278901No2004-05-242024-05-24Us
US7417070No2006-07-302026-07-30Us
US8410169No2010-02-132030-02-13Us
US9050311No2004-05-242024-05-24Us
US8252839No2004-05-242024-05-24Us
US8747897No2009-10-082029-10-08Us
US8349892No2011-01-222031-01-22Us
US9593066No2008-12-152028-12-15Us
US9604901No2008-12-152028-12-15Us
US9339507No2008-03-102028-03-10Us
US9358240No2008-05-052028-05-05Us
US9422223No2004-05-242024-05-24Us
US9393203No2006-04-272026-04-27Us
US9713599No2004-12-162024-12-16Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble at 25°CNot Available
logP4.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00731 mg/mLALOGPS
logP3.53ALOGPS
logP4ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.76ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity108 m3·mol-1ChemAxon
Polarizability45.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier+0.5541
Caco-2 permeable+0.5838
P-glycoprotein substrateSubstrate0.7733
P-glycoprotein inhibitor INon-inhibitor0.719
P-glycoprotein inhibitor IINon-inhibitor0.7518
Renal organic cation transporterNon-inhibitor0.8064
CYP450 2C9 substrateNon-substrate0.7811
CYP450 2D6 substrateNon-substrate0.8144
CYP450 3A4 substrateSubstrate0.6538
CYP450 1A2 substrateInhibitor0.7312
CYP450 2C9 inhibitorNon-inhibitor0.8496
CYP450 2D6 inhibitorNon-inhibitor0.9127
CYP450 2C19 inhibitorNon-inhibitor0.6214
CYP450 3A4 inhibitorNon-inhibitor0.6587
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6885
Ames testNon AMES toxic0.8716
CarcinogenicityNon-carcinogens0.9452
BiodegradationNot ready biodegradable0.7495
Rat acute toxicity2.0749 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9588
hERG inhibition (predictor II)Inhibitor0.7664
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Phenoxyacetic acid derivatives
Alternative Parents
Tetralins / Fatty alcohols / Alkyl aryl ethers / Secondary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Phenoxyacetate / Tetralin / Fatty alcohol / Alkyl aryl ether / Fatty acyl / Cyclic alcohol / Secondary alcohol / Carboxylic acid derivative / Carboxylic acid / Ether
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
carboxylic acid, carbotricyclic compound (CHEBI:50861)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name
PTGIR
Uniprot ID
P43119
Uniprot Name
Prostacyclin receptor
Molecular Weight
40955.485 Da
References
  1. Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH: Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010 Nov 1;182(9):1161-70. doi: 10.1164/rccm.201001-0011OC. Epub 2010 Jul 9. [PubMed:20622039]
  2. Sprague RS, Bowles EA, Hanson MS, DuFaux EA, Sridharan M, Adderley S, Ellsworth ML, Stephenson AH: Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes. Microcirculation. 2008 Jul;15(5):461-71. doi: 10.1080/10739680701833804. [PubMed:18574748]
  3. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004 May;102(2):139-53. [PubMed:15163595]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-lin...
Gene Name
PPARD
Uniprot ID
Q03181
Uniprot Name
Peroxisome proliferator-activated receptor delta
Molecular Weight
49902.99 Da
References
  1. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA: Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol. 2006 Feb;34(2):242-6. Epub 2005 Oct 20. [PubMed:16239641]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name
P2RY12
Uniprot ID
Q9H244
Uniprot Name
P2Y purinoceptor 12
Molecular Weight
39438.355 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K: Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010 Jul;50(7):829-34. doi: 10.1177/0091270009351173. Epub 2010 Feb 4. [PubMed:20133511]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49